Dame Emma Walmsley will step down as GSK’s chief executive at the end of the year, concluding nine years at the helm of Britain’s second-largest pharmaceuticals company.

The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).

The shares of GlaxoSmithKline ($GSK) cheered on Monday after the British pharmaceutical giant announced that its chief ...

Emma Walmsley, GSK's CEO, will be replaced by Luke Miels, the chief commercial officer, after almost nine years in the role.

We recently published 11 Stocks Crushing Wall Street With Whopping Gains. GSK plc (NYSE:GSK) is one of the top performers on ...

GSK's CEO Emma Walmsley will step down at the end of the year and be replaced by insider Luke Miels, the drugmaker said on ...

GSK plc names new CEO as shares rise 3% and maintains a 4% dividend yield; get key insights on GSK stock's outlook and what ...

Emma Walmsley was the first woman to hold the CEO post at the Big Pharma company.

Emma Walmsley, who in 2017 became the first woman to lead a major pharmaceutical company, will step down from her post as CEO ...

GSK Plc is “betting big on the US” and engaged in constructive talks on drug pricing with US President Donald Trump’s administration, according to Emma Walmsley, the outgoing chief executive officer ...

GSK Chief Executive Emma Walmsley, the first woman to lead a major pharmaceutical company, will step down Dec. 31 after more ...

British drugmaker GSK named insider Luke Miels as its CEO designate on Monday to succeed Emma Walmsley, who will step down ...